Literature DB >> 22944294

Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study.

Sylvia Hoeller1, Yi Zhou, Rashmi Kanagal-Shamanna, Zijun Y Xu-Monette, Daniela Hoehn, Michel Bihl, Steven H Swerdlow, Andreas Rosenwald, German Ott, Jonathan Said, Cherie H Dunphy, Carlos E Bueso-Ramos, Pei Lin, Michael Wang, Roberto N Miranda, Alexander Tzankov, L Jeffrey Medeiros, Ken H Young.   

Abstract

Mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) share many features and both arise from CD5+ B-cells; their distinction is critical as MCL is a more aggressive neoplasm. Rarely, cases of composite MCL and CLL/SLL have been reported. Little is known about the nature of these cases and, in particular, the clonal relationship of the 2 lymphomas. Eleven composite MCL and CLL/SLL cases were identified. The clinical, morphologic and immunophenotypic features of the MCL and CLL/SLL were characterized. IGH (immunoglobulin heavy chain) gene analysis was performed on microdissected MCL and CLL/SLL components to assess their clonal relationship. Ten patients had lymphadenopathy, and 7 patients had bone marrow involvement. The MCL component had the following growth patterns: in situ (n = 1), mantle zone (n = 3), nodular and diffuse (n = 3), diffuse (n = 3), and interstitial in the bone marrow (the only patient without lymphadenopathy) (n = 1); 6 MCLs had blastoid or pleomorphic and 5 small lymphocytic features. The CLL/SLL component was nodular (n = 9) or diffuse (n = 2). All MCL were CD5(+) and cyclin D1(+) with t(11;14) translocation. All CLL/SLL were CD5(+), CD23(+) and negative for cyclin D1 or t(11;14). IGH gene analysis showed that the MCL and CLL/SLL components displayed different sized fragments, indicating that the MCL and CLL/SLL are likely derived from different neoplastic B-cell clones. The lack of a clonal relationship between the MCL and CLL/SLL components suggests that MCL and CLL/SLL components represent distinct disease processes and do not share a common progenitor B-cell.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22944294      PMCID: PMC3640316          DOI: 10.1016/j.humpath.2012.04.022

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  28 in total

Review 1.  Familial chronic lymphocytic leukaemia: a survey and review of published studies.

Authors:  M R Yuille; E Matutes; A Marossy; B Hilditch; D Catovsky; R S Houlston
Journal:  Br J Haematol       Date:  2000-06       Impact factor: 6.998

2.  Composite mantle cell and diffuse large B-cell lymphoma: report of two cases.

Authors:  Albert K Ho; Carolin J Teman; Gregory P Smith; Daniel R Nightingale; Rodney R Miles
Journal:  Int J Surg Pathol       Date:  2011-10       Impact factor: 1.271

3.  Familial Aspects of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and Related Lymphomas.

Authors:  Lynn R Goldin; Ola Landgren; Gerald E Marti; Neil E Caporaso
Journal:  European J Clin Med Oncol       Date:  2010-02

4.  Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000.

Authors:  T Mitterlechner; M Fiegl; H Mühlböck; W Oberaigner; S Dirnhofer; A Tzankov
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

5.  Simultaneous evaluation of T- and B-cell clonality, t(11;14) and t(14;18), in a single reaction by a four-color multiplex polymerase chain reaction assay and automated high-resolution fragment analysis: a method for the rapid molecular diagnosis of lymphoproliferative disorders applicable to fresh frozen and formalin-fixed, paraffin-embedded tissues, blood, and bone marrow aspirates.

Authors:  V S Meier; A Rufle; F Gudat
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

6.  Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab.

Authors:  Taxiarchis V Kourelis; Brad S Kahl; Peter Benn; Judith A Delach; Syed F Bilgrami
Journal:  Acta Haematol       Date:  2011-03-23       Impact factor: 2.195

7.  Composite Hodgkin lymphoma and mantle cell lymphoma: two clonally unrelated tumors.

Authors:  Alessia Caleo; Abel Sánchez-Aguilera; Sandra Rodríguez; Ana M Dotor; Luis Beltrán; Aitor F de Larrinoa; Francisco J Menárguez; Miguel A Piris; Juan F García
Journal:  Am J Surg Pathol       Date:  2003-12       Impact factor: 6.394

Review 8.  Perspectives on familial chronic lymphocytic leukemia: genes and the environment.

Authors:  Neil Caporaso; Gerald E Marti; Lynn Goldin
Journal:  Semin Hematol       Date:  2004-07       Impact factor: 3.851

9.  Somatic hypermutation and V(H) gene usage in mantle cell lymphoma.

Authors:  Mia Thorsélius; Sarah Walsh; Inger Eriksson; Ulf Thunberg; Anna Johnson; Carin Backlin; Gunilla Enblad; Christer Sundström; Göran Roos; Richard Rosenquist
Journal:  Eur J Haematol       Date:  2002-04       Impact factor: 2.997

10.  Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database.

Authors:  Lynn R Goldin; Ruth M Pfeiffer; Xinjun Li; Kari Hemminki
Journal:  Blood       Date:  2004-05-25       Impact factor: 22.113

View more
  7 in total

Review 1.  Mantle cell lymphoma concurrent with T-large granular lymphocytic leukemia: report of a case and review of literature.

Authors:  Zhengrui Xiao; Ying Ni; Guangli Yin; Hanxin Wu; Jianyong Li; Kourong Miao
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.

Authors:  M Magni; M Di Nicola; C Patti; R Scimè; A Mulè; A Rambaldi; T Intermesoli; P Viero; C Tarella; A Gueli; L Bergui; L Trentin; A Barzan; F Benedetti; A Ambrosetti; F Di Raimondo; A Chiarenza; G Parvis; A Billio; I Attolico; A Olivieri; M Montanari; C Carlo-Stella; P Matteucci; L Devizzi; A Guidetti; S Viviani; P Valagussa; A M Gianni
Journal:  Bone Marrow Transplant       Date:  2014-01-20       Impact factor: 5.483

3.  The Effectiveness of Dual-Staining Immunohistochemistry in the Detection of Mantle Cell Lymphoma in the Bone Marrow.

Authors:  Ifeyinwa E Obiorah; Hao-Wei Wang; David Ma; Eddie Martin; Wyndham H Wilson; Raul Braylan
Journal:  Am J Clin Pathol       Date:  2022-05-04       Impact factor: 5.400

4.  Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features.

Authors:  Ifeyinwa Emmanuela Obiorah; Ivo M B Francischetti; Hao-Wei Wang; Inhye E Ahn; Weixin Wang; Mark Raffeld; Robert J Kreitman; Adrian Wiestner; Katherine R Calvo
Journal:  Leuk Lymphoma       Date:  2020-08-05

5.  Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.

Authors:  Mohan B Agarwal; Dinesh Bhurani; Chirag Shah; Nitin Sood; Manish Singhal; Anil Kamat; Subash Chezhian; Suryaprakash Mishra; Dinesh Nagrale
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Oct-Dec

Review 6.  Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.

Authors:  Arati A Inamdar; Andre Goy; Nehad M Ayoub; Christen Attia; Lucia Oton; Varun Taruvai; Mark Costales; Yu-Ting Lin; Andrew Pecora; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-26

Review 7.  A Rare Case of Composite Dural Extranodal Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Authors:  Mark Bustoros; Benjamin Liechty; David Zagzag; Cynthia Liu; Timothy Shepherd; Deborah Gruber; Bruce Raphael; Dimitris G Placantonakis
Journal:  Front Neurol       Date:  2018-04-24       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.